Assessing the Non-inferiority of the Single-dose Human Papillomavirus Vaccination Schedule: A Hypothetical Multi-country Cohort Study
What can you learn from this article? An experimental cohort study design for policy evaluation, where countries made the move from a two-dose to single-dose schedule for national HPV vaccination programmes since 2023.
Introduction Since the first licensing of the Human Papillomavirus (HPV) vaccine in 2006, evidence has been emerging showing that single-dose schedules provide comparable efficacy to the conditional regimens, i.e. two or three doses. In 2022, a review of World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) concluded that a single-dose HPV vaccine delivers solid protection against HPV.
2023-12-15